A Study of CLDN18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Pancreatic Cancer
Latest Information Update: 25 Sep 2021
At a glance
- Drugs LY 011 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Shanghai Longyao Biotechnology
- 23 Jul 2021 New trial record